Allergic Rhinitis Treatment Market Growth & Industry Outlook | Major Players 2025 - Merck & Co., Boehringer Ingelheim, GlaxoSmithKline PLC

"Allergic Rhinitis Treatment Market is Expected to reach at a CAGR of 6.9% during the forecast period (2024-2031)." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/allergic-rhinitis-treatment-market?sp

United States: Recent Industry Developments

✅ In September 2025, Sanofi launched a new intranasal biologic therapy for moderate-to-severe allergic rhinitis, targeting key inflammatory pathways. The treatment offers faster symptom relief and longer-lasting effects. It is designed for patients not responding to conventional antihistamines.

✅ In August 2025, GlaxoSmithKline (GSK) completed the acquisition of a U.S.-based biotech startup specializing in allergen immunotherapy for rhinitis. The acquisition expands GSK's allergy treatment portfolio. It supports accelerated clinical development and commercialization of innovative therapies.

✅ In July 2025, AstraZeneca invested $55 million in its U.S. research facility to develop next-generation allergy therapeutics, including combination biologic and small-molecule treatments. The investment enhances R&D capabilities. It aims to bring safer and more effective therapies to patients with seasonal and perennial rhinitis.

✅ In June 2025, Regeneron Pharmaceuticals launched a clinical study for a new monoclonal antibody targeting key IgE-mediated pathways in allergic rhinitis. The study evaluates efficacy, safety, and tolerability in U.S. patients. It supports expansion of Regeneron's allergy therapeutics pipeline.

Japan: Recent Industry Developments

✅ In September 2025, Takeda Pharmaceutical launched a new allergen-specific immunotherapy for Japanese patients with moderate-to-severe allergic rhinitis. The therapy offers sustained symptom control and improved quality of life. It targets both seasonal and perennial allergies.

✅ In August 2025, Daiichi Sankyo invested in expanding its allergy R&D division to develop next-generation biologics and small-molecule therapies for rhinitis. The initiative strengthens capabilities in immunotherapy and targeted treatments. It supports faster clinical development and patient access in Japan.

✅ In July 2025, Chugai Pharmaceutical completed the acquisition of a domestic biotech startup specializing in monoclonal antibodies for allergic diseases. The acquisition enhances its allergy treatment pipeline. It enables advanced research and quicker commercialization of innovative therapies.

✅ In June 2025, Shionogi & Co., Ltd. launched a Phase II/III clinical trial for a novel nasal spray targeting IgE-mediated allergic rhinitis in Japanese patients. The study focuses on safety, efficacy, and patient compliance. It aims to improve therapeutic options for moderate-to-severe allergy sufferers.

Allergic Rhinitis Treatment Market: Drivers

The allergic rhinitis treatment market is witnessing growth due to rising prevalence of seasonal and perennial allergies, driven by increasing air pollution, urbanization, and changing climatic conditions. Treatments, including antihistamines, corticosteroids, immunotherapy, and combination therapies, help manage symptoms such as nasal congestion, sneezing, and itching, improving patient quality of life. Growing awareness of allergy management, preventive care, and early diagnosis is encouraging patients to seek effective therapeutic solutions. Technological advancements in drug formulations, delivery mechanisms, and personalized treatment approaches are enhancing efficacy, convenience, and patient compliance. Additionally, expanding healthcare infrastructure and access to pharmacies and clinics are supporting market adoption.

Innovations in sublingual and subcutaneous immunotherapy, as well as combination nasal sprays, are providing more targeted and long-term treatment options. Integration with digital health tools and telemedicine platforms is enabling better disease monitoring, patient education, and adherence to therapy. The increasing focus on chronic disease management and reducing allergy-related complications is further driving demand for effective treatments. Collaborations between pharmaceutical companies, research institutions, and healthcare providers are accelerating clinical development and knowledge dissemination. Collectively, these factors are driving steady growth in the allergic rhinitis treatment market as healthcare systems and patients increasingly prioritize symptom relief, preventive care, and personalized therapeutic solutions.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/allergic-rhinitis-treatment-market?sp

Allergic Rhinitis Treatment Market: Major Players

Merck & Co., Boehringer Ingelheim, GlaxoSmithKline PLC, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Dr. Reddy's Laboratories, Mylan NV, Sun Pharmaceuticals, Stallergenes Greer

Segment Covered in the Allergic Rhinitis Treatment Market:

➥ By Drug Type: Antihistamines, Intranasal Corticosteroids, Immunotherapies, Decongestants, Others

➥ By Disease Type: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis

➥ By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Others

Research Process:

Both primary and secondary data sources have been used in the Allergic Rhinitis Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Allergic Rhinitis Treatment Market Research Industry:

➠ Who leads the Allergic Rhinitis Treatment industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Allergic Rhinitis Treatment market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Allergic Rhinitis Treatment market growth?
➠ What are the dominant sales and distribution strategies in the Allergic Rhinitis Treatment industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=allergic-rhinitis-treatment-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.